These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 263317)

  • 21. Dopamine and L-dopa: inhibition of thyrotropin-stimulated thyroidal thyroxine release.
    Maayan ML; Sellitto RV; Volpert EM
    Endocrinology; 1986 Feb; 118(2):632-6. PubMed ID: 2867890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion: evidence for an additional feedback mechanism in the control of thyroid hormone secretion.
    Feek CM; Sawers JS; Brown NS; Seth J; Irvine WJ; Toft AD
    J Clin Endocrinol Metab; 1980 Sep; 51(3):585-9. PubMed ID: 7410535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-dopa absorption and the pituitary-hypothalamic axis.
    Boyd AE; Angoff G; Long A; Mager M
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1341-7. PubMed ID: 263355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central nervous system and pituitary mechanisms in dopaminergic stimulation of growth hormone release in women.
    Ferrari C; Caldara R; Barbieri C; Testori GP; Benco R; Trezzi R; Crossignani RM; Rampini P
    Neuroendocrinology; 1981 Apr; 32(4):213-6. PubMed ID: 7219673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects.
    Camanni F; Massara F; Belforte L; Rosatello A; Molinatti GM
    J Clin Endocrinol Metab; 1977 Mar; 44(3):465-73. PubMed ID: 838847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium and calcium-antagonistic effects on prolactin and growth hormone responses to thyrotropin-releasing hormone and L-dopa in man.
    Röjdmark S; Andersson DE; Sundblad L
    J Clin Endocrinol Metab; 1981 Sep; 53(3):594-8. PubMed ID: 6790560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G
    Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma growth hormone responses to sulpiride in patients with acromegaly.
    Hanew K; Sato S; Sasaki A; Kasai M; Shimizu Y; Murakami O; Yoshinaga K
    Tohoku J Exp Med; 1984 Apr; 142(4):445-52. PubMed ID: 6429896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients.
    Esel E; Kartalci S; Tutus A; Turan T; Sofuoglu S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):303-9. PubMed ID: 14751427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional characterization of hypothalamic hyperprolactinemia.
    Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
    J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome].
    Wu X; Gu Q; Su Y
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):489-91. PubMed ID: 9639745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
    Rabey JM; Vardi Y; Ravid R; Ayalon D
    Horm Res; 1981; 15(2):78-87. PubMed ID: 6799381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation.
    Ferrari C; Rampini P; Paracchi A; Boghen M; Mailland F
    Eur J Clin Pharmacol; 1985; 27(6):707-11. PubMed ID: 3921384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatotroph responsiveness to low dose dopamine infusion in normal subjects and acromegalic patients.
    Serri O
    Neuroendocrinology; 1986; 42(6):475-80. PubMed ID: 3010156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral thyrotropin-releasing hormone (TRH) test in acromegaly.
    Marek J; Límanová Z; Srámková J
    Endokrinologie; 1981 Oct; 78(1):57-66. PubMed ID: 6797816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential TSH and PRL responses to dopamine receptor blockade in acromegaly.
    Prescott RW; Weightman DR; Kendall-Taylor P; Johnston DG
    Clin Endocrinol (Oxf); 1984 Oct; 21(4):369-75. PubMed ID: 6509782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noradrenergic and dopaminergic regulation of GH and prolactin in baboons.
    Steiner RA; Illner P; Rolfs AD; Toivola PT; Gale CC
    Neuroendocrinology; 1978; 26(1):15-31. PubMed ID: 209362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia.
    Kelley SR; Kamal TJ; Molitch ME
    Am J Physiol; 1996 Jan; 270(1 Pt 1):E96-100. PubMed ID: 8772480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women.
    Petraglia F; De Leo V; Sardelli S; Mazzullo G; Gioffrè WR; Genazzani AR; D'Antona N
    Gynecol Obstet Invest; 1987; 23(2):103-9. PubMed ID: 3583091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.